Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Robert Chess Insider Profile
4 Followers
Robert Chess, Director at Nektar Therapeutics, holds 60.70K shares in Twist Bioscience (Ticker: TWST), holds 261.57K shares in Nektar Therapeutics (Ticker: NKTR). Most recently, Robert Chess Sold ― shares of Twist Bioscience on Feb 11, 2025 for an estimated value of 156.20K.
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+10.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Robert Chess holds in companies
Most Profitable Insider Trade
The most profitable trade made by Robert Chess
Robert Chess's Trading History
Nektar Therapeutics
Jun 14, 2024
Director
Uninformative Sell
23.40K
$250.06K
Twist Bioscience
Feb 11, 2025
Director
Informative Sell
156.20K
$2.74M
List of latest transactions for each holding click on a transaction to see Robert Chess's performance on stock
You May Also Like
Robert Chess insider profile FAQ
What is the percentage of profitable transactions made by Robert Chess?
The percentage of profitable transactions made by Robert Chess is 50%.
What is the average return per transaction made by Robert Chess?
The average return per transaction made by Robert Chess is 10.20%.
What stocks does Robert Chess hold?
Robert Chess holds: NKTR, TWST stocks.
What was Robert Chess’s latest transaction?
Robert Chess latest transaction was an Informative Sell of $156.20K.
What was Robert Chess's most profitable transaction?
Robert Chess’s most profitable transaction was an Informative Sell of TWST stock on February 8, 2022. The return on the trade was 57.40%.
What is Robert Chess's role in Nektar Therapeutics?
Robert Chess's role in Nektar Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.